The tweet was deleted by the author.
But we saved everything 🙂.
Vir Biotechnology has announced it will release its financial results for the third quarter of 2026 on Wednesday, November 4, immediately following the close of U.S. markets.
The company has scheduled an investor conference call at 4:30 p.m. ET (1:30 p.m. PT) to discuss its latest corporate updates and financial performance. Investors and stakeholders are invited to join the session via the provided link.
View post on X Loading...
Vir Biotechnology recently partnered with Gilead Sciences in a multi-program agreement to develop dual-masked TCEs for solid tumor therapies, as reported here. The company is also advancing its Phase 3 ECLIPSE program for a potential Hepatitis Delta treatment, aiming to address unmet medical needs according to previous updates. These initiatives follow a series of clinical and strategic developments in 2026.